List view / Grid view

Bayer HealthCare



Targovax appoints of Øystein Soug as CEO

4 November 2016 | By Niamh Louise Marriott, Digital Content Producer

Øystein Soug is the former CFO of Algeta, a Norwegian oncology biotech company which was sold to Bayer for USD 2.9 billion in 2014...


Molecular Target Validation in preclinical drug discovery

2 May 2014 | By , , ,

Preclinical drug target validation has the aim to increase confidence in a particular drug target. The process proves the initial hypothesis that a particular molecular target is key or even causative for pathogenic or symptomatic mechanisms in a disease. Several success factors seem to be of particular importance for the…